Corneal Regeneration Using Gene Therapy Approaches

Ocular Pathology and Genetics: Transformative Role of Artificial Intelligence (AI) in Anterior Segment Diseases

Artificial intelligence (AI) has become a revolutionary influence in the field of ophthalmology, providing unparalleled capabilities in data analysis and pattern recognition. This narrative review delves into the crucial role that AI plays, particularly in the context of anterior segment diseases with a genetic basis. Corneal dystrophies (CDs) exhibit significant genetic diversity, manifested by irregular substance deposition in the cornea. AI-driven diagnostic tools exhibit promising accuracy in the identification and classification of corneal diseases. Importantly, chat generative pre-trained transformer (ChatGPT)-4.0 shows significant advancement over its predecessor, ChatGPT-3.5. In the realm of glaucoma, AI significantly contributes to precise diagnostics through inventive algorithms and machine learning models, surpassing conventional methods. The incorporation of AI in predicting glaucoma progression and its role in augmenting diagnostic efficiency is readily apparent. Additionally, AI-powered models prove beneficial for early identification and risk assessment in cases of congenital cataracts, characterized by diverse inheritance patterns. Machine learning models achieving exceptional discrimination in identifying congenital cataracts underscore AI's remarkable potential. The review concludes by emphasizing the promising implications of AI in managing anterior segment diseases, spanning from early detection to the tailoring of personalized treatment strategies. These advancements signal a paradigm shift in ophthalmic care, offering optimism for enhanced patient outcomes and more streamlined healthcare delivery.

Current Advances in Regenerative Strategies for Dry Eye Diseases: A Comprehensive Review

Dry eye disease (DED) is an emerging health issue affecting millions of individuals annually. Ocular surface disorders, such as DED, are characterized by inflammation triggered by various factors. This condition can lead to tear deficiencies, resulting in the desiccation of the ocular surface, corneal ulceration/perforation, increased susceptibility to infections, and a higher risk of severe visual impairment and blindness. Currently, the clinical management of DED primarily relies on supportive and palliative measures, including the frequent and lifelong use of different lubricating agents. While some advancements like punctal plugs, non-steroidal anti-inflammatory drugs, and salivary gland autografts have been attempted, they have shown limited effectiveness. Recently, there have been promising developments in the treatment of DED, including biomaterials such as nano-systems, hydrogels, and contact lenses for drug delivery, cell-based therapies, biological approaches, and tissue-based regenerative therapy. This article specifically explores the different strategies reported so far for treating DED. The aim is to discuss their potential as long-term cures for DED while also considering the factors that limit their feasibility and effectiveness. These advancements offer hope for more effective and sustainable treatment options in the future.